Chimeric antigen receptor T-cell immunotherapy has developed rapidly in recent years, but it has not achieved ideal results in the treatment of solid tumors represented by glioblastoma. This paper briefly reviews the current situation of the treatment of glioblastoma, introduces the therapeutic principle and effective target of chimeric antigen receptor T cells, analyzes the reasons why the curative effect is not significant, and summarizes the promising improvement strategies at present.